GT Biopharma, Inc.GTBPNASDAQ
Loading
Book Value/Share Growth AcceleratingAccelerating
Percentile Rank74
3Y CAGR-55.8%
5Y CAGR-12.2%
Year-over-Year Change
Year-over-year book value per share growth
3Y CAGR
-55.8%/yr
Quarterly compound
5Y CAGR
-12.2%/yr
Recent deceleration
Percentile
P74
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 37.88% |
| Q3 2025 | -56.19% |
| Q2 2025 | 515.85% |
| Q1 2025 | 52.53% |
| Q4 2024 | -193.79% |
| Q3 2024 | -70.82% |
| Q2 2024 | -16.36% |
| Q1 2024 | -28.95% |
| Q4 2023 | -26.03% |
| Q3 2023 | -16.69% |
| Q2 2023 | -27.18% |
| Q1 2023 | 21.62% |
| Q4 2022 | 437.85% |
| Q3 2022 | -87.57% |
| Q2 2022 | -9.70% |
| Q1 2022 | 548.56% |
| Q4 2021 | -91.69% |
| Q3 2021 | -6.21% |
| Q2 2021 | -26.77% |
| Q1 2021 | 2547.98% |
| Q4 2020 | 72.53% |
| Q3 2020 | -1.45% |
| Q2 2020 | -28.52% |
| Q1 2020 | -5.28% |
| Q4 2019 | 96.97% |
| Q3 2019 | -5495.76% |
| Q2 2019 | -11.82% |
| Q1 2019 | -12.79% |
| Q4 2018 | -97.18% |
| Q3 2018 | -94.59% |
| Q2 2018 | -2.46% |
| Q1 2018 | 2906.64% |
| Q4 2017 | -98.94% |
| Q3 2017 | 139.11% |
| Q2 2017 | 8.48% |
| Q1 2017 | -1244.79% |
| Q4 2016 | 98.21% |
| Q3 2016 | 0.18% |
| Q2 2016 | 34.67% |
| Q1 2016 | 0.00% |